With completed Phase 1 and 2 clinical trials in non-small-cell lung cancer (NSCLC), BeyondSpring has a strong body of safety and efficacy data suggesting that a combination therapy of Plinabulin and commonly-used chemotherapy drug docetaxel can extend the overall survival of targeted late-stage NSCLC patients.
Based on consultation with the U.S. FDA, BeyondSpring are conduc

Valley Life Sciences Institute life commitment, wisdom, angel investors, major research new rapid low-cost disposable electrochemical biosensor device immunity, the principle means has been completed and received international PCT patent. The project is expected to lead to disruptive technology revolution, it has broad commercial prospects.